Loading company…
PolyActiva develops biodegradable implants for sustained drug release, aimed at ophthalmic diseases such as glaucoma.
Founded in 2010 and headquartered in Melbourne, Australia, PolyActiva Pty Ltd develops biodegradable drug delivery implants for patients with ophthalmic diseases, particularly glaucoma. Its lead product, PA5108, uses the Prezia Sustained Drug Delivery Technology platform. CEO Russell Tait leads the company, which completed 4 deals and raised AUD 40 million in a Series C round on 30 May 2025, led by the National Reconstruction Fund Corporation with Brandon Capital Partners participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in